COMMUNIQUÉS West-GlobeNewswire
-
Zacks Small Cap Research Initiates Coverage on Pressure BioSciences, Inc.
04/10/2019 - 14:04 -
Cynata Advances Toward Phase 2 Clinical Trial of Cymerus(TM) MSCs in Patients with Osteoarthritis
04/10/2019 - 14:05 -
Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock
04/10/2019 - 14:30 -
Assure Holdings Announces Issuance of Options Under Stock Option Plan
04/10/2019 - 14:30 -
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Highlight Camelina Platform for Producing PHB Biomaterials to Improve Water Quality at International Scientific Conference
04/10/2019 - 14:30 -
Conformis Announces Departure of Paul Weiner, CFO
04/10/2019 - 14:30 -
Sarepta Therapeutics Announces Positive Functional Results from the SRP-9003 (MYO-101) Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
04/10/2019 - 14:31 -
Pixium Vision apporte des précisions sur la participation de Omnes Capital, inchangée depuis fin 2017
04/10/2019 - 15:49 -
Pixium Vision provides clarification on Omnes Capital shareholding, unchanged since end 2017
04/10/2019 - 16:17 -
DBV Technologies annonce l'acceptation par la FDA du dépôt de sa demande de sa Licence Biologique pour Viaskin Peanut, un traitement de l'allergie aux arachides
04/10/2019 - 17:45 -
DBV Technologies Announces FDA Acceptance of BLA filing for Viaskin Peanut for the Treatment of Peanut Allergy
04/10/2019 - 17:45 -
Press news Biocartis Group NV: Disclosure of a transparency notification
04/10/2019 - 07:00 -
Statement re: Appointment of Corporate Broker
04/10/2019 - 08:00 -
Chi-Med Initiates an International Phase I/Ib Trial of HMPL-523 in Patients with Advanced Relapsed or Refractory Lymphoma
04/10/2019 - 08:39 -
Fulcrum Therapeutics Announced Results of Phase 1 Clinical Trial of Losmapimod in FSHD
04/10/2019 - 10:30 -
NOTICE TO DISREGARD – Dabir Surfaces
04/10/2019 - 04:01 -
Ovid Therapeutics Announces Proposed Concurrent Public Offerings of Common Stock and Preferred Stock
03/10/2019 - 22:01 -
Entasis Therapeutics Announces Multiple Presentations at ID Week 2019
03/10/2019 - 22:01 -
Aptevo Therapeutics Provides Corporate and Pipeline Update
03/10/2019 - 22:02
Pages